Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
Plos Neglected Tropical Diseases
|
December 27, 2023
Dynamics of chikungunya virus transmission in the first year after its introduction in Brazil: A cohort study in an urban community
Rosângela O Anjos, Moyra M Portilho, Leile Camila Jacob-Nascimento, et al.
International Journal for Equity in Health
|
October 9, 2025
Prevalence of chronic non-communicable diseases and multimorbidity among adults living in slums in Rio de Janeiro, Brazil: a population-based survey
Amanda Echeverría-Guevara, Paula M Luz, Débora C Pires, et al.
PLOS Global Public Health
|
December 15, 2025
Food insecurity and associated factors during the COVID-19 pandemic in a vulnerable population in Rio de Janeiro: A primary care registry-based survey
Alessandra C V Meireles, Paula M Luz, Daniel Csillag, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 10, 2017
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Ellen C Caniglia, Andrew Phillips, Kholoud Porter, et al.
Lancet Regional Health. Americas
|
August 8, 2022
Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey
Lara E Coelho, Paula M Luz, Débora C Pires, et al.
The Lancet. HIV
|
August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Journal of the International AIDS Society
|
August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
Anchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
Lancet Regional Health. Americas
|
July 12, 2024
SARS-CoV-2 transmission in a highly vulnerable population of Brazil: a household cohort study
Lara E Coelho, Paula M Luz, Débora C Pires, et al.
Plos One
|
January 21, 2022
COVID-19 vaccine hesitancy and associated factors according to sex: A population-based survey in Salvador, Brazil
Nivison Nery, Juan P Aguilar Ticona, Cristiane W Cardoso, et al.
Lancet Regional Health. Americas
|
April 18, 2022
In-hospital mortality and severe outcomes after hospital discharge due to COVID-19: A prospective multicenter study from Brazil
Hugo Perazzo, Sandra W Cardoso, Maria Pia D Ribeiro, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
Plos Neglected Tropical Diseases
|
December 27, 2023
Dynamics of chikungunya virus transmission in the first year after its introduction in Brazil: A cohort study in an urban community
Rosângela O Anjos, Moyra M Portilho, Leile Camila Jacob-Nascimento, et al.
International Journal for Equity in Health
|
October 9, 2025
Prevalence of chronic non-communicable diseases and multimorbidity among adults living in slums in Rio de Janeiro, Brazil: a population-based survey
Amanda Echeverría-Guevara, Paula M Luz, Débora C Pires, et al.
PLOS Global Public Health
|
December 15, 2025
Food insecurity and associated factors during the COVID-19 pandemic in a vulnerable population in Rio de Janeiro: A primary care registry-based survey
Alessandra C V Meireles, Paula M Luz, Daniel Csillag, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 10, 2017
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Ellen C Caniglia, Andrew Phillips, Kholoud Porter, et al.
Lancet Regional Health. Americas
|
August 8, 2022
Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey
Lara E Coelho, Paula M Luz, Débora C Pires, et al.
The Lancet. HIV
|
August 3, 2019
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, et al.
Journal of the International AIDS Society
|
August 30, 2022
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
Anchalee Avihingsanon, Michael D Hughes, Robert Salata, et al.
Lancet Regional Health. Americas
|
July 12, 2024
SARS-CoV-2 transmission in a highly vulnerable population of Brazil: a household cohort study
Lara E Coelho, Paula M Luz, Débora C Pires, et al.
Plos One
|
January 21, 2022
COVID-19 vaccine hesitancy and associated factors according to sex: A population-based survey in Salvador, Brazil
Nivison Nery, Juan P Aguilar Ticona, Cristiane W Cardoso, et al.
Lancet Regional Health. Americas
|
April 18, 2022
In-hospital mortality and severe outcomes after hospital discharge due to COVID-19: A prospective multicenter study from Brazil
Hugo Perazzo, Sandra W Cardoso, Maria Pia D Ribeiro, et al.
Page
of 13